Promising cancer drug study halted early
NCT ID NCT06478862
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 20 times
Summary
This study tested a drug called Promitil in people with ovarian or pancreatic cancer that had specific gene mutations (BRCA or related). The goal was to see if the drug could control the cancer after first treatment stopped working. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rambam Health Care Campus
Haifa, Israel
-
Shaare Zedek Medical Center
Jerusalem, 9103102, Israel
-
Shamir Medical Center (Asaf Harofeh)
Ẕerifin, 70300, Israel
-
Soroka Medical Center
Beersheba, Israel
-
Tel-Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
Wolfson Medica Center
Holon, 5822012, Israel
Conditions
Explore the condition pages connected to this study.